Fate Therapeutics, Inc.

Historical 13F Holders

Symbol
FATE
CUSIP
31189P102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 31189P102 since 12/18/2024, newest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A Amendment 8 1.9% 7/8/2026
Event 6/30/2026
Redmile Group, LLC 13D/A Amendment 10
14.9% 4/22/2026
Event 4/20/2026
Vanguard Group Inc 13G/A Amendment 6 0% 3/26/2026
Event 3/13/2026
Schonfeld Strategic Advisors LLC 13G/A Amendment 1 0.8% 8/14/2025
Event 6/30/2025
Goldman Sachs Group Inc 13G/A Amendment 1
2.0% 8/14/2025
Event 6/30/2025
Vanguard Group Inc 13G/A Amendment 5 7.6% 7/29/2025
Event 6/30/2025
Redmile Group, LLC 13D/A Amendment 9
14.9% 7/3/2025
Event 7/2/2025
Schonfeld Strategic Advisors LLC 13G 6.8% 5/15/2025
Event 3/31/2025
Goldman Sachs Group Inc 13G
7.4% 5/9/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 7 6.9% 4/23/2025
Event 3/31/2025
Redmile Group, LLC 13D/A Amendment 8
14.9% 12/26/2024
Event 12/20/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 1.58 k $3.75 k
2026 Q2 162 71.7 M $194 M
2026 Q1 163 74.1 M $88.9 M
2025 Q4 151 72.3 M $71.1 M
2025 Q3 147 80.6 M $102 M
2025 Q2 145 79.8 M $89.1 M
2025 Q1 137 96.6 M $76.3 M
2024 Q4 164 102 M $166 M
2024 Q3 169 117 M $408 M
2024 Q2 191 127 M $416 M
2024 Q1 180 131 M $962 M
2023 Q4 166 99.5 M $372 M
2023 Q3 175 95.7 M $203 M
2023 Q2 198 109 M $520 M
2023 Q1 191 113 M $642 M
2022 Q4 242 112 M $1.13 B
2022 Q3 252 109 M $2.45 B
2022 Q2 247 110 M $2.70 B
2022 Q1 270 101 M $3.93 B
2021 Q4 270 97.2 M $5.68 B
2021 Q3 284 95.9 M $5.68 B
2021 Q2 290 94.5 M $8.20 B
2021 Q1 279 94.0 M $7.75 B
2020 Q4 276 87.7 M $7.98 B
2020 Q3 228 87.8 M $3.51 B
2020 Q2 219 86.0 M $2.95 B
2020 Q1 174 80.1 M $1.78 B
2019 Q4 162 73.1 M $1.43 B
2019 Q3 159 77.5 M $1.22 B
2019 Q2 148 63.2 M $1.28 B
2019 Q1 131 60.8 M $1.07 B
2018 Q4 131 60.1 M $771 M
2018 Q3 126 55.2 M $898 M
2018 Q2 110 43.1 M $489 M
2018 Q1 93 39.5 M $385 M
2017 Q4 79 35.3 M $216 M
2017 Q3 74 25.4 M $101 M
2017 Q2 60 26.6 M $86.2 M
2017 Q1 54 25.6 M $117 M
2016 Q4 38 23.7 M $59.3 M
2016 Q3 40 19.5 M $60.8 M
2016 Q2 40 14.1 M $24.0 M
2016 Q1 46 15.8 M $28.4 M
2015 Q4 54 18.6 M $62.7 M
2015 Q3 44 18.3 M $97.8 M
2015 Q2 39 18.0 M $117 M
2015 Q1 25 10.6 M $51.9 M
2014 Q4 24 10.3 M $51.8 M
2014 Q3 22 10.3 M $52.6 M
2014 Q2 23 9.89 M $62.7 M
2014 Q1 21 9.56 M $92.8 M